FILANA THERAPEUTICS INC

FLNANASDAQ

🏆 #3553 by market capEarnings Oct 29US Equity

$0.97▼ $0.04 (−3.81%)

Market closed · at close

1h—

24h▼ 3.8%

7d▼ 1.0%

14d▲ 12.0%

30d▼ 14.8%

1y▼ 58.3%

🏦Market Cap

$47M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

17.8%

Healthy

⚖️P/S Ratio

1.2x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $0.95 – $0.98
52-Week Range: $0.86 – $2.27
Volume: $2.56B
Avg Volume: $2.81B
Shares Outstanding: 48.3M
Next Earnings: Oct 5, 2026

Fundamentals Snapshot

Annual Revenue: $41M
Last Q Revenue: $10M
P/E Ratio: —
P/S Ratio: 1.2x
EPS (TTM): $-0.88
Dividend Yield: —

Why Investors Own FLNA

✓High-growth profile — revenue up +39.5% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$41M▲ +43.2% YoY

Gross Margin (TTM)

61.7%▲ +1.7% YoY

Operating Income (TTM)

$6M▲ +43.2% YoY

Free Cash Flow (TTM)

$2M▲ +43.2% YoY

About FILANA THERAPEUTICS INC

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

🦦